C
Carlotta Zerbinati
Researcher at University of Ferrara
Publications - 13
Citations - 763
Carlotta Zerbinati is an academic researcher from University of Ferrara. The author has contributed to research in topics: Apoptosis & Tumor necrosis factor alpha. The author has an hindex of 12, co-authored 13 publications receiving 717 citations. Previous affiliations of Carlotta Zerbinati include University of Trieste.
Papers
More filters
Journal ArticleDOI
Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL).
Paola Secchiero,Paola Secchiero,Elisa Barbarotto,Elisa Barbarotto,Mario Tiribelli,Mario Tiribelli,Carlotta Zerbinati,Carlotta Zerbinati,Maria Grazia di Iasio,Maria Grazia di Iasio,Arianna Gonelli,Arianna Gonelli,Francesco Cavazzini,Francesco Cavazzini,Diana Campioni,Diana Campioni,Renato Fanin,Renato Fanin,Antonio Cuneo,Antonio Cuneo,Giorgio Zauli,Giorgio Zauli +21 more
TL;DR: The induction of p53 by nutlin-3 in B-CLL samples was accompanied by alterations of the mitochondrial potential and activation of the caspase-dependent apoptotic pathway and the profile of gene activation showed a partial overlapping with that induced by the genotoxic drug fludarabine.
Journal ArticleDOI
TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells
Paola Secchiero,Carlotta Zerbinati,Erika Rimondi,Federica Corallini,Daniela Milani,Vittorio Grill,G Forti,Silvano Capitani,Giorgio Zauli +8 more
TL;DR: Western blot analysis consistently showed that TRAIL induced a significant activation of ERK1/2, and a much weaker phosphorylation of Akt, while it did not affect the p38/MAPK pathway.
Journal ArticleDOI
Pluripotent Stem Cell miRNAs and Metastasis in Invasive Breast Cancer
Stefano Volinia,Gerard J. Nuovo,Alessandra Drusco,Stefan Costinean,Ramzey Abujarour,Caroline Desponts,Michela Garofalo,Raffaele Baffa,Rami Aeqilan,Kati Maharry,Maria Elena Sana Ramiro Garzon,Gianpiero Di Leva,Pierluigi Gasparini,Paola Dama,Jlenia Marchesini,Marco Galasso,Marco Manfrini,Carlotta Zerbinati,Fabio Corrà,Timothy F. Wise,Sylwia E. Wojcik,Maurizio Previati,Flavia Pichiorri,Nicola Zanesi,Hansjuerg Alder,Jeff Palatini,Kay Huebner,Charles L. Shapiro,Massimo Negrini,Andrea Vecchione,Anne L. Rosenberg,Carlo M. Croce +31 more
TL;DR: In invasive ductal carcinoma, the MIR302/MIR203 asymmetry was associated with stem cell markers, metastasis, and shorter survival, and overall survival was statistically significantly shorter in patients with MIR 302-positive cancer cells.
Journal ArticleDOI
TRAIL inhibits osteoclastic differentiation by counteracting RANKL-dependent p27Kip1 accumulation in pre-osteoclast precursors.
Giorgio Zauli,Erika Rimondi,Susanna Stea,Fabio Baruffaldi,Marco Stebel,Carlotta Zerbinati,Federica Corallini,Paola Secchiero +7 more
TL;DR: The data strongly suggest that recombinant TRAIL inhibits osteoclastogenesis by inducing the ubiquitin‐mediated degradation of p27Kip1.
Journal ArticleDOI
Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells.
Paola Secchiero,Carlotta Zerbinati,Maria Grazia di Iasio,Elisabetta Melloni,Mario Tiribelli,Vittorio Grill,Giorgio Zauli +6 more
TL;DR: The combined treatment of nutlin-3 plus TRAIL might offer a novel therapeutic strategy for AML and the relevance of p21 down-regulation for sensitizing AML cells to apoptosis was underscored in knocking-down experiments with small interfering RNAs.